The rapid correction of hypercalcemia at presentation of acute lymphoblastic leukemia using high-dose methylprednisolone

Turkish Journal of Pediatrics

Volumn 50, Issue 2, 2008, Pages 171-175

  Ünal, Şule ^a   Durmaz, Erdem ^a   Erkoçoǧlu, Mustafa ^a   Bayrakçi, Benan ^a   Bircan, Özlem ^a   Alikaşifoǧlu, Ayfer ^a   Çetin, Mualla ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; Children; Hypercalcemia; Methylprednisolone

Indexed keywords

CALCITONIN; CALCIUM; CREATININE; DAUNORUBICIN; FUROSEMIDE; METHYLPREDNISOLONE; NITROGEN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE; UREA; VINCRISTINE; VITAMIN D;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMUR FRACTURE; HUMAN; HUMERUS FRACTURE; HYDRATION; HYPERCALCEMIA; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; T CELL LEUKEMIA; UREA NITROGEN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

CHILD, PRESCHOOL; HUMANS; HYPERCALCEMIA; MALE; METHYLPREDNISOLONE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 48649103295     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. McKay C, Furman WL. Hypercalcemia complicating childhood malignancies. Cancer 1993; 72: 256-260.
2. Leblanc A, Caillaud JM, Hartmann O, et al. Hypercalcemia preferentially occurs in unusual forms of childhood non-Hodgkin's lymphoma, rhabdomyosarcoma, and Wilms' tumor. A study of 11 cases. Cancer 1984; 54: 2132-2136.
3. Kerdudo C, Aerts I, Fattet S, et al. Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr Hematol Oncol 2005; 27: 23-27.
4. Warrell RP Jr. Metabolic emergencies. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology (5th ed). Philadelphia, Pa: Lippincott-Raven Publishers; 1997: 2486-2493.
5. Harutsumi M, Akazai A, Kitamura T, et al. A case of acute lymphoblastic leukemia accompanied with the production of parathyroid hormone-related protein. Miner Electrolyte Metab 1995; 21: 171-176.
6. Mundy GR, Martin TJ. The hypercalcemia of malignancy: pathogenesis and management. Metabolism 1982; 31: 1247-1277.
7. Broadus AE, Mangin M, Ikeda K, et al. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med 1988; 319: 556-563.
8. Horiuchi N, Caulfield MP, Fisher JE, et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987; 238: 1566-1568.
9. Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237: 893-896.
10. Oda N, Nakai A, Hayashi R, et al. Utility of measuring serum parathyroid hormone-related protein concentration in leukemic patients with hypercalcemia for assessing disease status. Eur J Endocrinol 1998; 139: 323-329.
11. Hibi S, Funaki H, Ochiai-Kanai R, et al. Hypercalcemia in children presenting with acute lymphoblastic leukemia. Int J Hematol 1997; 66: 353-357.
12. Dodwell DJ. Malignant bone resorption: cellular and biochemical mechanisms. Ann Oncol 1992; 3: 257-267.
13. Coleman RE. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. Oncology (Huntingt) 1991; 5: 55-60.
14. Thiébaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med 1990; 150: 2125-2128.
15. Parsons V, Baum M, Self M. Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease. Br Med J 1967; 1: 474-477.
16. Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia. Acta Oncol 1992; 31: 861-864.
17. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT. Comparison of amino-hydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; 2: 907-910.
18. Elomaa I, Blomqvist C, Porkka L, et al. Diphosphonates for osteolytic metastases. Lancet 1985; 1: 1155-1156.
19. Mundy GR, Rick ME, Turcotte R, Kowalski MA. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. Am J Med 1978; 65: 600-606.
20. Ralston SH, Fogelman I, Gardiner MD, Boyle IT. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) 1984; 288: 1405-1408.
21. Schwartz CL, Thompson EB, Gelber RD, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001; 19: 1040-1046.
22. Gustafsson JA, Carlstedt-Duke J, Poellinger L, et al. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev 1987; 8: 185-234.
23. Gehring U. Genetics of glucocorticoid receptors. Mol Cell Endocrinol 1986; 48: 89-96.
24. Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, Borowitz MJ. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. Cancer Res 1985; 45: 6482-6486.
25. Yetgin S, Olgar S, Aras T, et al. Evaluation of kidney damage in patients with acute lymphoblastic leukemia in long-term follow-up: value of renal scan. Am J Hematol 2004; 77: 132-139.
26. Yetgin S, Tuncer MA, Çetin M, et al. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003; 17: 328-333.